Barclays’s Annovis Bio ANVS Stock Holding History

Barclays’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.47K	Buy	+1,866	New	+$3.63K	﹤0.01%	4816
2025 Q2	–	Sell	-2	Closed	-$3	–	5243
2025 Q1	$3	Buy	+2	New	+$6	﹤0.01%	5201

Other funds holding ANVS

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's ANVS Position: Q2 2026 in Review

Barclays opened a new position in Annovis Bio (ANVS) in Q2 2026: 1,866 shares worth $3.47K. The stake represents ﹤0.01% of the portfolio and ranks #4816 among its holdings. This is a return to the name: Barclays previously reported a position in ANVS as recently as Q1 2025.

Barclays first reported a position in ANVS in Q1 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

Barclays held 1,866 shares of Annovis Bio worth $3.47K as of Q2 2026.
Annovis Bio was a new Barclays position in Q2 2026.
Annovis Bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4816 holding.
Barclays first reported a position in Annovis Bio in Q1 2025 and has held it in 2 quarters since.
61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.